The U.S. Food and Drug Administration today expanded the approved use of Nucala (mepolizumab) to treat adult patients with eosinophilic granulomatosis with polyangiitis (EGPA), a rare autoimmune disease that causes vasculitis, an inflammation in the wall of blood vessels of the body. This new indication provides the first FDA-approved therapy specifically to treat EGPA.

Mayo Clinic’s Todd and Karen Wanek Family Program for Hypoplastic Left Heart Syndrome and Children’s Minnesota are collaborating to prevent heart failure for hypoplastic left heart syndrome, a rare and complex form of congenital heart disease in which the left side of a child's heart is severely underdeveloped.

The holiday season often brings unwelcome guests - stress and depression. And it's no wonder. The holidays present a dizzying array of demands - parties, shopping, baking, cleaning and entertaining, to name just a few.

Remarks from FDA Commissioner Scott Gottlieb, M.D., as prepared for oral testimony before the U.S. Senate Committee on Health, Education, Labor & Pensions Hearing, “Implementation of the 21st Century Cures Act: Progress and the Path Forward for Medical Innovation:

The American Red Cross appreciates all heroes who make room in their schedules during the busy holiday season to help patients in need. Since its launch over two years ago, the Red Cross RapidPass® continues to help save time for blood and platelet donors. RapidPass is now compatible with most mobile devices, offering even more convenience to donors.

The American Heart Association (AHA) and the American Medical Association (AMA) today recognized 310 physician practices and health systems from across the country for their commitment to reducing the number of Americans who have heart attacks and strokes each year. These physician practices and health systems are the first-ever to receive awards through the AHA and AMA's new Target: BP Recognition Program.